Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States.

Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP.

MBio. 2011 Jan 25;2(1):e00309-10. doi: 10.1128/mBio.00309-10.

2.

Trends in U.S. hospitalizations and inpatient deaths from pneumonia and influenza, 1996-2011.

Chang DH, Bednarczyk RA, Becker ER, Hockenberry JM, Weiss PS, Orenstein WA, Omer SB.

Vaccine. 2016 Jan 20;34(4):486-94. doi: 10.1016/j.vaccine.2015.12.003. Epub 2015 Dec 17.

PMID:
26706275
3.
4.

Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.

Rubin JL, McGarry LJ, Klugman KP, Strutton DR, Gilmore KE, Weinstein MC.

BMC Infect Dis. 2010 Jan 21;10:14. doi: 10.1186/1471-2334-10-14.

5.

U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.

Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG.

N Engl J Med. 2013 Jul 11;369(2):155-63. doi: 10.1056/NEJMoa1209165.

6.

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.

Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks.

Vaccine. 2015 Jan 3;33(2):359-66. doi: 10.1016/j.vaccine.2014.11.011. Epub 2014 Nov 20.

PMID:
25448105
7.

Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua.

Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R, Alemán J, Hudgens MG, Woods CW, Weber DJ.

Pediatr Infect Dis J. 2014 Jun;33(6):637-42. doi: 10.1097/INF.0000000000000269.

PMID:
24445827
8.

Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine (PCV-10) in Children in Chile: A Nested Case-Control Study Using Nationwide Pneumonia Morbidity and Mortality Surveillance Data.

Diaz J, Terrazas S, Bierrenbach AL, Toscano CM, Alencar GP, Alvarez A, Valenzuela MT, Andrus J, del Aguila R, Hormazábal JC, Araya P, Pidal P, Matus CR, de Oliveira LH.

PLoS One. 2016 Apr 8;11(4):e0153141. doi: 10.1371/journal.pone.0153141. eCollection 2016.

9.

Pneumococcal pneumonia and influenza: a deadly combination.

Klugman KP, Chien YW, Madhi SA.

Vaccine. 2009 Aug 21;27 Suppl 3:C9-C14. doi: 10.1016/j.vaccine.2009.06.007.

PMID:
19683658
10.

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.

Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, Krajden S, Ostrowska K, Richardson D, Richardson S, Sarabia A, Silverman M, Simor AE, Tyrrell G, McGeer A; Toronto Invasive Bacterial Diseases Network.

Vaccine. 2013 Dec 2;31(49):5863-71. doi: 10.1016/j.vaccine.2013.09.049. Epub 2013 Oct 5.

PMID:
24099873
11.

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR.

Lancet. 2007 Apr 7;369(9568):1179-86.

PMID:
17416262
12.

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.

Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP.

Lancet Respir Med. 2014 May;2(5):387-94. doi: 10.1016/S2213-2600(14)70032-3. Epub 2014 Mar 10.

PMID:
24815804
13.

Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.

Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez M, Saez M, Soldevila N, Astray J, Mayoral JM, Martín V, Quintana JM, González-Candelas F, Galán JC, Tamames S, Castro A, Baricot M, Garín O, Pumarola T; CIBERESP Cases and Controls in Pandemic Influenza Working Group (Spain).

Hum Vaccin Immunother. 2013 Apr;9(4):865-73. doi: 10.4161/hv.23090. Epub 2013 Apr 1.

14.

Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults.

Shafinoori S, Ginocchio CC, Greenberg AJ, Yeoman E, Cheddie M, Rubin LG.

Pediatr Infect Dis J. 2005 Jan;24(1):10-6.

PMID:
15665704
15.

Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine.

Li ST, Tancredi DJ.

Pediatrics. 2010 Jan;125(1):26-33. doi: 10.1542/peds.2009-0184. Epub 2009 Nov 30. Erratum in: Pediatrics. 2010 Feb;125(2):415.

PMID:
19948570
16.

Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States.

Tsai CJ, Griffin MR, Nuorti JP, Grijalva CG.

Clin Infect Dis. 2008 Jun 1;46(11):1664-72. doi: 10.1086/587897.

17.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
18.

Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical.

Newall AT, Reyes JF, McIntyre P, Menzies R, Beutels P, Wood JG.

Vaccine. 2016 Jan 12;34(3):320-7. doi: 10.1016/j.vaccine.2015.11.053. Epub 2015 Dec 2.

PMID:
26657187
19.

Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 Jan 16;58(1):1-4.

20.

The worldwide impact of the seven-valent pneumococcal conjugate vaccine.

Fitzwater SP, Chandran A, Santosham M, Johnson HL.

Pediatr Infect Dis J. 2012 May;31(5):501-8. doi: 10.1097/INF.0b013e31824de9f6.

PMID:
22327872

Supplemental Content

Support Center